Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol.
A combined DST-sequential CyA therapy protocol has been described that results in optimum graft survival for 1- and 2-haplotype mismatched living related donor-recipient combinations. In addition to the excellent graft survival obtained through 4 years, lower prednisone and CyA dosage levels are achieved with significantly decreased infection rates during the posttransplant period.
Salvatierra
O
O
Transplant Service, University of California, San Francisco 94143-0116.
McVicar
J
J
Melzer
J
J
Amend
W
W
Vincenti
F
F
Tomlanovich
S
S
Husing
R
R
Rabkin
J
J
Garovoy
M
M
D001803:Blood Transfusion; D003141:Communicable Diseases / Q000150:complications; D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection; D006085:Graft Survival; D006239:Haplotypes; D006648:Histocompatibility; D006801:Humans; D006973:Hypertension / Q000150:complications; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D014019:Tissue Donors
D011241:Prednisone